Literature DB >> 29805654

Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells.

Tomohiro Tanaka1, Tatsuhiko Ozawa2, Eiji Oga1, Atsushi Muraguchi2, Hiroaki Sakurai1.   

Abstract

The aberrant activation of receptor tyrosine kinases (RTKs) is associated with tumor initiation in various types of human cancer, including non-small cell lung cancers (NSCLCs). Tyrosine kinase-independent non-canonical RTK regulation has also been investigated in tumor malignant alterations, including cellular stress responses. It was recently reported that the phosphorylation of epidermal growth factor receptor (EGFR) at C-terminal Ser-1015 serves a critical role in growth factor and cytokine signaling. In the present study, the role of non-canonical EGFR regulation has been investigated in NSCLC cells treated with cisplatin, a common chemotherapeutic agent. Cisplatin-induced p38 activation triggered the Ser-1015 phosphorylation of EGFR, with similar kinetics to previously reported Ser-1047 phosphorylation, in a tyrosine kinase-independent manner. In addition, phosphorylation around Ser-1015 triggered endocytosis of a dimer deficient mutant of EGFR. The non-canonical endocytosis of EGFR monomers was primarily controlled by the region around Ser-1015 only; however, Ser-1047 on internalized EGFR was equally phosphorylated. The results of the present study provide mechanistic evidence for the cisplatin-induced non-canonical regulation of EGFR.

Entities:  

Keywords:  and non-small cell lung cancer cells; cisplatin; endocytosis; epidermal growth factor receptor; p38

Year:  2018        PMID: 29805654      PMCID: PMC5958650          DOI: 10.3892/ol.2018.8485

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

1.  Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9.

Authors:  Alaa Refaat; Yue Zhou; Shunsuke Suzuki; Ichiro Takasaki; Keiichi Koizumi; Shoji Yamaoka; Yoshiaki Tabuchi; Ikuo Saiki; Hiroaki Sakurai
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

Review 2.  Epidermal growth factor receptor targeting in cancer.

Authors:  John Mendelsohn; Jose Baselga
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

3.  Improved Phos-tag SDS-PAGE under neutral pH conditions for advanced protein phosphorylation profiling.

Authors:  Eiji Kinoshita; Emiko Kinoshita-Kikuta
Journal:  Proteomics       Date:  2010-12-14       Impact factor: 3.984

4.  Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress.

Authors:  Jiefei Tong; Paul Taylor; Michael F Moran
Journal:  Mol Cell Proteomics       Date:  2014-05-05       Impact factor: 5.911

5.  A kinase-independent role for EGF receptor in autophagy initiation.

Authors:  Xiaojun Tan; Narendra Thapa; Yue Sun; Richard A Anderson
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

Review 6.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

7.  TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling.

Authors:  Miki Nishimura; Myoung-Sook Shin; Pattama Singhirunnusorn; Shunsuke Suzuki; Miho Kawanishi; Keiichi Koizumi; Ikuo Saiki; Hiroaki Sakurai
Journal:  Mol Cell Biol       Date:  2009-08-17       Impact factor: 4.272

Review 8.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

9.  Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.

Authors:  Yue Zhou; Naoki Yamada; Tomohiro Tanaka; Takashi Hori; Satoru Yokoyama; Yoshihiro Hayakawa; Seiji Yano; Junya Fukuoka; Keiichi Koizumi; Ikuo Saiki; Hiroaki Sakurai
Journal:  Nat Commun       Date:  2015-07-09       Impact factor: 14.919

Review 10.  EGF receptor trafficking: consequences for signaling and cancer.

Authors:  Alejandra Tomas; Clare E Futter; Emily R Eden
Journal:  Trends Cell Biol       Date:  2013-11-29       Impact factor: 20.808

View more
  4 in total

1.  Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes.

Authors:  Denisa Bojkova; Sandra Westhaus; Rui Costa; Lejla Timmer; Nora Funkenberg; Marek Korencak; Hendrik Streeck; Florian Vondran; Ruth Broering; Stefan Heinrichs; Karl S Lang; Sandra Ciesek
Journal:  Cells       Date:  2020-04-17       Impact factor: 6.600

2.  Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane.

Authors:  Vinaya Phatak; Yannick von Grabowiecki; Justyna Janus; Leah Officer; Caron Behan; Lydia Aschauer; Lucia Pinon; Hannah Mackay; Sara Zanivan; Jim C Norman; Michael Kelly; John Le Quesne; Patricia A J Muller
Journal:  Cell Death Dis       Date:  2021-02-24       Impact factor: 8.469

3.  Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells.

Authors:  Elisabete Cruz Da Silva; Laurence Choulier; Jessica Thevenard-Devy; Christophe Schneider; Philippe Carl; Philippe Rondé; Stéphane Dedieu; Maxime Lehmann
Journal:  Cells       Date:  2021-11-21       Impact factor: 6.600

4.  Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis.

Authors:  Jun-Ichiro Takahashi; Shiori Nakamura; Iimi Onuma; Yue Zhou; Satoru Yokoyama; Hiroaki Sakurai
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.